Darya-Varia Laboratoria Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 4/6
Darya-Varia Laboratoria's earnings have been declining at an average annual rate of -11.6%, while the Pharmaceuticals industry saw earnings growing at 15.7% annually. Revenues have been growing at an average rate of 1.4% per year. Darya-Varia Laboratoria's return on equity is 13.1%, and it has net margins of 9.1%.
Anahtar bilgiler
-11.6%
Kazanç büyüme oranı
-11.7%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 20.4% |
| Gelir büyüme oranı | 1.4% |
| Özkaynak getirisi | 13.1% |
| Net Marj | 9.1% |
| Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Gelir ve Gider Dağılımı
Darya-Varia Laboratoria nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 24 | 2,134,031 | 193,905 | 861,683 | 0 |
| 30 Jun 24 | 1,995,668 | 169,381 | 820,850 | 0 |
| 31 Mar 24 | 1,910,016 | 152,911 | 804,351 | 0 |
| 31 Dec 23 | 1,890,888 | 146,336 | 797,516 | 0 |
| 30 Sep 23 | 1,739,189 | 83,901 | 800,934 | 0 |
| 30 Jun 23 | 1,815,693 | 76,354 | 848,585 | 0 |
| 31 Mar 23 | 1,783,948 | 73,275 | 838,027 | 0 |
| 31 Dec 22 | 1,917,041 | 149,375 | 830,427 | 0 |
| 30 Sep 22 | 1,856,945 | 43,735 | 902,083 | 0 |
| 30 Jun 22 | 2,009,621 | 182,520 | 836,609 | 0 |
| 31 Mar 22 | 2,058,892 | 202,596 | 822,550 | 0 |
| 31 Dec 21 | 1,900,894 | 146,505 | 806,071 | 0 |
| 30 Sep 21 | 2,120,581 | 282,843 | 760,233 | 0 |
| 30 Jun 21 | 1,876,676 | 156,427 | 749,778 | 0 |
| 31 Mar 21 | 1,834,423 | 186,516 | 703,353 | 0 |
| 31 Dec 20 | 1,829,700 | 162,073 | 726,548 | 0 |
| 30 Sep 20 | 1,680,412 | 191,500 | 640,392 | 0 |
| 30 Jun 20 | 1,827,255 | 246,976 | 656,609 | 0 |
| 31 Mar 20 | 1,814,913 | 195,056 | 704,992 | 0 |
| 31 Dec 19 | 1,813,020 | 221,783 | 678,004 | 0 |
| 30 Sep 19 | 1,875,188 | 214,986 | 725,281 | 0 |
| 30 Jun 19 | 1,799,139 | 206,116 | 699,069 | 0 |
| 31 Mar 19 | 1,750,915 | 221,007 | 659,471 | 0 |
| 31 Dec 18 | 1,699,657 | 200,652 | 675,336 | 0 |
| 30 Sep 18 | 1,598,083 | 153,113 | 686,445 | 0 |
| 30 Jun 18 | 1,597,357 | 149,482 | 693,798 | 0 |
| 31 Mar 18 | 1,607,717 | 141,526 | 717,529 | 0 |
| 31 Dec 17 | 1,575,647 | 162,249 | 681,339 | 0 |
| 30 Sep 17 | 1,515,073 | 187,072 | 636,347 | 0 |
| 30 Jun 17 | 1,479,646 | 189,754 | 614,137 | 0 |
| 31 Mar 17 | 1,470,354 | 179,081 | 603,725 | 0 |
| 31 Dec 16 | 1,451,357 | 152,083 | 596,507 | 0 |
| 30 Sep 16 | 1,472,526 | 147,533 | 595,355 | 0 |
| 30 Jun 16 | 1,399,810 | 113,992 | 599,284 | 0 |
| 31 Mar 16 | 1,343,054 | 104,633 | 580,192 | 0 |
| 31 Dec 15 | 1,306,098 | 107,894 | 558,135 | 0 |
| 30 Sep 15 | 1,269,185 | 101,501 | 534,569 | 0 |
| 30 Jun 15 | 1,290,566 | 108,668 | 526,546 | 0 |
| 31 Mar 15 | 1,228,853 | 158,858 | 465,139 | 0 |
| 31 Dec 14 | 1,103,822 | 81,598 | 486,345 | 0 |
| 30 Sep 14 | 1,073,326 | 108,552 | 451,640 | 0 |
| 30 Jun 14 | 985,453 | 97,391 | 449,895 | 0 |
| 31 Mar 14 | 1,032,137 | 64,584 | 523,405 | 0 |
| 31 Dec 13 | 1,101,684 | 125,796 | 511,748 | 0 |
Kaliteli Kazançlar: DVLA has high quality earnings.
Büyüyen Kar Marjı: DVLA's current net profit margins (9.1%) are higher than last year (4.8%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: DVLA's earnings have declined by 11.6% per year over the past 5 years.
Büyüme Hızlandırma: DVLA's earnings growth over the past year (131.1%) exceeds its 5-year average (-11.6% per year).
Kazançlar vs. Sektör: DVLA earnings growth over the past year (131.1%) exceeded the Pharmaceuticals industry 4%.
Özkaynak Getirisi
Yüksek ROE: DVLA's Return on Equity (13.1%) is considered low.